KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Financing Activities (2016 - 2025)

Neogenomics' Cash from Financing Activities history spans 16 years, with the latest figure at $431000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 37.26% year-over-year to $431000.0; the TTM value through Dec 2025 reached -$200.3 million, down 4410.98%, while the annual FY2025 figure was -$200.3 million, 4410.98% down from the prior year.
  • Cash from Financing Activities reached $431000.0 in Q4 2025 per NEO's latest filing, down from $765000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $524.9 million in Q1 2021 to a low of -$202.4 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $27.3 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: soared 84978.61% in 2021, then tumbled 10396.69% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.5 million in 2021, then fell by 26.75% to $1.8 million in 2022, then dropped by 29.52% to $1.3 million in 2023, then tumbled by 45.91% to $687000.0 in 2024, then plummeted by 37.26% to $431000.0 in 2025.
  • Per Business Quant, the three most recent readings for NEO's Cash from Financing Activities are $431000.0 (Q4 2025), $765000.0 (Q3 2025), and -$202.4 million (Q2 2025).